DE60305443D1 - Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung - Google Patents

Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung

Info

Publication number
DE60305443D1
DE60305443D1 DE60305443T DE60305443T DE60305443D1 DE 60305443 D1 DE60305443 D1 DE 60305443D1 DE 60305443 T DE60305443 T DE 60305443T DE 60305443 T DE60305443 T DE 60305443T DE 60305443 D1 DE60305443 D1 DE 60305443D1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
improved
general transmission
vivo general
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60305443T
Other languages
English (en)
Other versions
DE60305443T2 (de
Inventor
Bruno Pitard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of DE60305443D1 publication Critical patent/DE60305443D1/de
Publication of DE60305443T2 publication Critical patent/DE60305443T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60305443T 2002-02-08 2003-02-07 Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung Expired - Lifetime DE60305443T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0201584A FR2835749B1 (fr) 2002-02-08 2002-02-08 Composition pharmaceutique ameliorant le transfert de gene in vivo
FR0201584 2002-02-08
PCT/FR2003/000407 WO2003066104A2 (fr) 2002-02-08 2003-02-07 Composition pharmaceutique ameliorant le transfert de gene in vivo

Publications (2)

Publication Number Publication Date
DE60305443D1 true DE60305443D1 (de) 2006-06-29
DE60305443T2 DE60305443T2 (de) 2007-05-10

Family

ID=27620039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60305443T Expired - Lifetime DE60305443T2 (de) 2002-02-08 2003-02-07 Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung

Country Status (10)

Country Link
US (2) US7709452B2 (de)
EP (1) EP1471944B1 (de)
JP (1) JP4613011B2 (de)
AT (1) ATE326986T1 (de)
AU (1) AU2003222896A1 (de)
CA (1) CA2473212C (de)
DE (1) DE60305443T2 (de)
ES (1) ES2265569T3 (de)
FR (1) FR2835749B1 (de)
WO (1) WO2003066104A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868953B1 (fr) * 2004-04-16 2006-06-30 Inst Nat Sante Rech Med Composition pour le transfert intracellulaire d'un acide nucleique.
MX2009002856A (es) * 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Conjugados polimericos que contienen porciones cargadas positivamente.
DE102006051623A1 (de) 2006-11-02 2008-07-31 Horn, Peter A. Verfahren und Stoffgemisch zur Verbesserung eines in vivo Genfransfers
WO2010026537A1 (en) 2008-09-05 2010-03-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel multimodular assembly useful for intracellular delivery
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4015005A1 (de) 2011-10-03 2022-06-22 ModernaTX, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und ihre verwendungen
SG11201402666WA (en) 2011-12-16 2014-10-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013106558A1 (en) 2012-01-10 2013-07-18 Merial Limited Lipid based adjuvants for dna - plasmid vaccines
WO2013128424A1 (en) 2012-03-02 2013-09-06 Institut National De La Sante Et De La Recherche Medicale Vaccine for prophylaxis or treatment of an allergen-driven and/or a chronic airways disease
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243955B2 (en) 2012-04-02 2018-02-22 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20150182620A1 (en) 2012-06-15 2015-07-02 Inserm (Institut De La Sante Et De La Recherche Medicale) Polypeptides for use in the Prophylactic Treatment of Allergic Asthma
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (zh) 2013-10-03 2016-09-28 现代治疗公司 编码低密度脂蛋白受体的多核苷酸
ES2759243T3 (es) 2014-04-01 2020-05-08 Inst Nat Sante Rech Med Moléculas de ARN protegidas y no protegidas y copolímeros de bloques para la administración intracelular de ARN
EP3225246A1 (de) 2016-03-31 2017-10-04 Klinikum der Universität München Synthetische verbindung zur verbesserung der effizienz der transfektion
US20210000917A1 (en) 2018-03-05 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and composition for the treatment of allergic asthma
WO2020182901A1 (en) * 2019-03-11 2020-09-17 Evaxion Biotech Aps Nucleic acid vaccination using neo-epitope encoding constructs
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
GB9216082D0 (en) * 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
CA2315256A1 (en) * 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
GB9904627D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Polymer compositions for polynucleotide delivery
AU4898699A (en) 1999-07-16 2001-02-05 Reatech Phosphor addition in gasification
AU6389000A (en) * 1999-07-28 2001-02-19 Valentis, Inc. Sonoporation of tumors
WO2001060415A1 (en) 2000-02-18 2001-08-23 The Immune Response Corporation Methods and compositions for gene delivery
AU2001241958A1 (en) * 2000-03-03 2001-09-17 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
WO2002061040A2 (en) 2000-10-20 2002-08-08 Valentis, Inc. Gene delivery formulations and methods for treatment of ischemic conditions

Also Published As

Publication number Publication date
EP1471944A2 (de) 2004-11-03
AU2003222896A8 (en) 2003-09-02
DE60305443T2 (de) 2007-05-10
WO2003066104A2 (fr) 2003-08-14
JP4613011B2 (ja) 2011-01-12
JP2005522433A (ja) 2005-07-28
US7709452B2 (en) 2010-05-04
CA2473212A1 (fr) 2003-08-14
EP1471944B1 (de) 2006-05-24
FR2835749A1 (fr) 2003-08-15
AU2003222896A1 (en) 2003-09-02
WO2003066104A3 (fr) 2004-03-25
ATE326986T1 (de) 2006-06-15
US20100179212A1 (en) 2010-07-15
US20050152870A1 (en) 2005-07-14
CA2473212C (fr) 2013-04-23
US8367631B2 (en) 2013-02-05
ES2265569T3 (es) 2007-02-16
FR2835749B1 (fr) 2006-04-14

Similar Documents

Publication Publication Date Title
DE60305443D1 (de) Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung
BR0213802A (pt) Copolìmero útil para a preparação de géis de ácidos
BR0116004A (pt) Derivados de 6-o-carbamoil cetolida de eritromicina úteis como antibacterianos
ATE551988T1 (de) Orale zusammensetzungen, ihre herstellung und verwendung
DK1366104T3 (da) Miljömæssigt nedbrydelige polymere forbindelser, deres fremstilling og anvendelse som hot-melt klæbestof
HK1033743A1 (en) Adhesive composition and method for producing it.
JO2707B1 (ar) مشتقات ثيوفين جليكوسايد جديدة, طرق تحضيرها, والادوية المحتوية على هذه المركبات واستخدامها
GB0415365D0 (en) Pyrimidine derivatives
WO2003016282A3 (en) Substituted 1h-dihydropyrazoles, their preparation and use
ATE485049T1 (de) Physiologisch aktive zusammensetzung gegen diabetes
WO2004017998A3 (en) Topical emulsion- gel composition comprising diclofenac sodium
TR200102131T2 (tr) Matrisk metaloproteinaz inhitörleri olarak 2,3,4,5-tetrahidro-1H[1,4] benzodiyazepin-3- hidroksamik asitler.
ATE354622T1 (de) Flüssigkristallines medium
MXPA04004621A (es) Nucleotidos, preparaciones de los mismos y su utilizacion como inhibidores de polimerasas virales de arn.
BR0211903A (pt) Isoxazolopiridinonas
TW200502235A (en) Novel benzo[1,2,5]thiadiazoles and pharmaceutical use thereof
WO2005055937A3 (en) Branched sulfates with improved odor properties and their use in personal care compositions
NO20025209D0 (no) Cyklipostiner, deres fremstilling og anvendelse
DE60203890D1 (de) Apfelsäureadditionssalze von terbinafin
WO2000043375A3 (de) Substituierte arylheterocyclen
TW200610491A (en) Pesticidal agents
WO2003044038A3 (en) Biologically active complex
SE0101323D0 (sv) New process
WO2001059087A3 (en) Compositions for transfecting nucleic acids and their use
WO2008071689A3 (en) Process for the manufacture of alkylamino alkylene phosphonic acids

Legal Events

Date Code Title Description
8364 No opposition during term of opposition